◀ Back to IL6
ESR1 — IL6
Pathways - manually collected, often from reviews:
Text-mined interactions from Literome
Speirs et al., Br J Cancer 2000
(Breast Neoplasms) :
In conclusion, these results provide evidence for direct transcriptional
activation of
ERalpha by
IL-6
Baykal et al., Clin Rheumatol 2003
(Familial Mediterranean Fever) :
In FMF patients
IL-6 , TNF-alpha, sIL-2r,
ESR , CRP and fibrinogen levels
increased with the acute-phase reaction, especially in the attack period
Liu et al., Cytokine 2005
:
Estrogen receptor inhibits
interleukin-6 gene expression by disruption of nuclear factor kappaB transactivation
Yang et al., Cytokine 2009
(Ovarian Neoplasms) :
The
effect of
IL-6 and IL-8 on activation of estrogen-responsive promoter as well as
estrogen receptor (ER)alpha and ER beta expression was also analyzed
Danforth et al., Cancer Res 1993
(Breast Neoplasms) :
IL-1 or
IL-6 alone each
down-regulated the
estrogen receptor ( 36.7 %, P < 0.01, and 23.2 %, P < 0.05, respectively ), but the combination IL-1 + IL-6 did not cause a significantly greater effect than IL-1 alone
Galien et al., Nucleic Acids Res 1997
(Bone Neoplasms...) :
Estrogen receptor impairs
interleukin-6 expression by preventing protein binding on the NF-kappaB site
Ray et al., FEBS Lett 1997
(Adenocarcinoma...) :
We previously showed that inhibition of
IL-6 gene expression by E2 does not
involve high-affinity binding of the
estrogen receptor ( ER ) to IL-6 DNA